[go: up one dir, main page]

PE20160853A1 - Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) - Google Patents

Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)

Info

Publication number
PE20160853A1
PE20160853A1 PE2016000787A PE2016000787A PE20160853A1 PE 20160853 A1 PE20160853 A1 PE 20160853A1 PE 2016000787 A PE2016000787 A PE 2016000787A PE 2016000787 A PE2016000787 A PE 2016000787A PE 20160853 A1 PE20160853 A1 PE 20160853A1
Authority
PE
Peru
Prior art keywords
copd
pulmonary disease
chronic obstructive
obstructive pulmonary
combined therapy
Prior art date
Application number
PE2016000787A
Other languages
English (en)
Inventor
Sauro Bonelli
Enrico Zambelli
Francesca Usberti
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42107420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160853(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of PE20160853A1 publication Critical patent/PE20160853A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/003—Adding propellants in fluid form to aerosol containers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B7/00—Closing containers or receptacles after filling
    • B65B7/16—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons
    • B65B7/28—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
    • B65B7/2842—Securing closures on containers
    • B65B7/285—Securing closures on containers by deformation of the closure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)

Abstract

Se refiere a una composicion en aerosol para inhaladores presurizados de dosis medidas que comprende: a) bromuro de glicopirronio a una dosis en el intervalo de 0,5 a 100 ug por accionamiento, b) formoterol o una sal del mismo en una dosis de 1 a 25 micogramos por accionamiento; disueltos en un propelente de HFA y un cosolvente que es etanol, ademas dicha composicion contiene HCl 1M en el rango de 0,1 y 0,3 microgramos/microlitros. Opcionalmente, la formulacion comprende dipropionato de beclometasona. Dicha composicion es util para administrar en pacientes con EPOC
PE2016000787A 2009-12-23 2010-12-22 Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) PE20160853A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09180671 2009-12-23

Publications (1)

Publication Number Publication Date
PE20160853A1 true PE20160853A1 (es) 2016-09-14

Family

ID=42107420

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012000865A PE20121396A1 (es) 2009-12-23 2010-12-22 Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol
PE2016000787A PE20160853A1 (es) 2009-12-23 2010-12-22 Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012000865A PE20121396A1 (es) 2009-12-23 2010-12-22 Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol

Country Status (40)

Country Link
US (3) US20110150782A1 (es)
EP (1) EP2515855B3 (es)
JP (2) JP5914354B2 (es)
KR (2) KR101757951B1 (es)
CN (2) CN102665679B (es)
AR (2) AR079726A1 (es)
AU (3) AU2010334859A1 (es)
BR (1) BR112012015337B8 (es)
CA (1) CA2785321C (es)
CL (1) CL2012001705A1 (es)
CO (1) CO6541628A2 (es)
CY (2) CY1115116T1 (es)
DK (1) DK2515855T6 (es)
EA (2) EA021917B1 (es)
ES (1) ES2468840T7 (es)
FI (2) FI2515855T6 (es)
GE (1) GEP20156311B (es)
HR (1) HRP20140582T4 (es)
HU (1) HUS1800001I1 (es)
IL (1) IL260932B (es)
LT (1) LTC2515855I2 (es)
LU (1) LUC00060I2 (es)
MA (1) MA33823B1 (es)
MX (1) MX2012006878A (es)
MY (1) MY156949A (es)
NL (1) NL300923I2 (es)
NO (1) NO2018001I1 (es)
NZ (1) NZ600790A (es)
PE (2) PE20121396A1 (es)
PH (1) PH12012501066A1 (es)
PL (1) PL2515855T6 (es)
PT (1) PT2515855E (es)
RS (1) RS53391B2 (es)
SG (1) SG181868A1 (es)
SI (1) SI2515855T1 (es)
TN (1) TN2012000269A1 (es)
TW (1) TWI495468B (es)
UA (1) UA113832C2 (es)
WO (1) WO2011076843A2 (es)
ZA (1) ZA201204615B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2515855T6 (da) * 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
WO2011076841A2 (en) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
PT2515854E (pt) 2009-12-23 2014-05-27 Chiesi Farma Spa Formulação de aerossol para dpoc
EP2749280A3 (en) * 2011-02-17 2014-08-20 Cipla Limited Combination of glycopyrronium and formoterol
PL2765994T3 (pl) * 2011-10-11 2019-09-30 Chiesi Farmaceutici S.P.A. Krystaliczne mikrocząstki beta-agonisty pokryte kwasem tłuszczowym
JP2016503390A (ja) * 2012-10-23 2016-02-04 シプラ・リミテッド 医薬組成物
ES2699986T3 (es) 2013-07-11 2019-02-13 Chiesi Farm Spa Formulación de polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico para administración por inhalación
CA2935305C (en) * 2013-12-30 2022-07-12 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
TN2016000262A1 (en) * 2013-12-30 2017-10-06 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination.
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
GB201416909D0 (en) * 2014-09-25 2014-11-12 Prosonix Ltd Method of forming concentrated solution
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
LT3377108T (lt) 2015-11-16 2020-07-10 Chiesi Farmaceutici S.P.A. Inhaliacinių miltelių kompozicijos, apimančios anticholinerginį agentą, kortikosteroidą ir beta adrenerginį agentą, paruošimo būdas
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
MA43782A (fr) 2016-03-31 2021-04-28 Chiesi Farm Spa Dispositif d'inhalation d'aérosol
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
JP6781828B2 (ja) 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
US20190374519A1 (en) * 2016-09-19 2019-12-12 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
PE20191043A1 (es) 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica
US10350164B2 (en) 2017-05-11 2019-07-16 Chiesi Farmaceutici S.P.A. Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
CN110582269B (zh) * 2017-05-11 2023-02-28 奇斯药制品公司 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
MA52756A (fr) * 2018-06-04 2021-04-14 Lupin Inc Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression
KR102835735B1 (ko) * 2019-12-02 2025-07-21 키에시 파르마슈티시 엣스. 피. 에이. 가압 정량 흡입기를 위한 스테인리스 스틸 캔
CN115989032A (zh) 2020-07-31 2023-04-18 化学研究有限公司 用于吸入施用的组合疗法
JP2023546025A (ja) 2020-10-09 2023-11-01 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧定量吸入器のための医薬製剤
CA3257044A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. PHARMACEUTICAL FORMULATION FOR PRESSURIZED DOSING AEROSOL
CN119255820A (zh) 2022-05-27 2025-01-03 奇斯药制品公司 用于加压定量吸入器的药物制剂
CN119630425A (zh) 2022-05-27 2025-03-14 奇斯药制品公司 用于加压定量吸入器的药物制剂

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
DE69324161T2 (de) * 1992-12-09 1999-10-28 Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield Stabilisierte medizinische aerosollösungen
CN1158996C (zh) * 1998-07-24 2004-07-28 杰格研究股份公司 药用气溶胶制剂
DK1102579T3 (da) * 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
UA73986C2 (uk) * 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
EP1372608B1 (de) 2001-03-30 2007-10-10 Jagotec Ag Medizinische aerosolformulierungen
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
ATE465712T1 (de) 2002-03-01 2010-05-15 Chiesi Farma Spa Ultrafeine zusammensetzungen von formoterol
CA2510043A1 (en) 2002-12-16 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing hfc solution formulations
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
DK1713473T3 (da) 2004-02-06 2013-06-17 Meda Pharma Gmbh & Co Kg Kombination af anticholinergika og glucocorticoider til langtidsbehandling af astma og COPD
CA2550841C (en) * 2004-02-06 2012-10-02 Meda Pharma Gmbh & Co. Kg Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1616567A1 (en) 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
GB0505545D0 (en) 2005-03-17 2005-04-27 Glaxo Group Ltd Inhalation devices
EP1879620A2 (en) 2005-03-30 2008-01-23 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
EP1912691A4 (en) 2005-08-01 2012-08-22 Astrazeneca Ab VALVE OF INHALER
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
JP5107933B2 (ja) 2005-12-21 2012-12-26 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 炎症性疾患の治療に使用する、抗コリン作用薬類、β２−アドレナリン受容体のアゴニスト類、抗ロイコトリエン（ロイコトリエン受容体のアンタゴニスト）類、グルココルチコイド類および／またはＰＤＥ４阻害剤類の新規配合薬
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
WO2009051818A1 (en) 2007-10-18 2009-04-23 Stiefel Research Australia Pty Ltd Topical glycopyrrolate formulations
CA2764867C (en) * 2009-06-09 2016-05-17 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
WO2011076841A2 (en) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
DK2515855T6 (da) * 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
PT2515854E (pt) * 2009-12-23 2014-05-27 Chiesi Farma Spa Formulação de aerossol para dpoc
CN102695496B (zh) * 2009-12-23 2014-10-01 奇斯药制品公司 用于copd的气雾剂制剂
ES2699986T3 (es) * 2013-07-11 2019-02-13 Chiesi Farm Spa Formulación de polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico para administración por inhalación
TN2016000262A1 (en) * 2013-12-30 2017-10-06 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination.
CA2935305C (en) * 2013-12-30 2022-07-12 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Also Published As

Publication number Publication date
AU2010334859A1 (en) 2012-07-12
AU2016234895B2 (en) 2018-02-01
FIC20170064I1 (fi) 2017-12-29
PE20121396A1 (es) 2012-10-24
RS53391B2 (sr) 2023-09-29
PL2515855T6 (pl) 2023-12-18
SI2515855T1 (sl) 2014-08-29
KR20170040392A (ko) 2017-04-12
WO2011076843A3 (en) 2011-12-01
US20150328144A1 (en) 2015-11-19
WO2011076843A2 (en) 2011-06-30
AR115897A2 (es) 2021-03-10
BR112012015337A2 (pt) 2016-03-15
US11389401B2 (en) 2022-07-19
GEP20156311B (en) 2015-07-10
LTC2515855I2 (lt) 2019-05-10
IL260932B (en) 2021-04-29
MY156949A (en) 2016-04-15
CA2785321A1 (en) 2011-06-30
JP6283388B2 (ja) 2018-02-21
EA027778B1 (ru) 2017-08-31
KR20120103653A (ko) 2012-09-19
US10159645B2 (en) 2018-12-25
EP2515855A2 (en) 2012-10-31
CN104055765A (zh) 2014-09-24
NZ600790A (en) 2014-09-26
AR079726A1 (es) 2012-02-15
JP5914354B2 (ja) 2016-05-11
PT2515855E (pt) 2014-06-11
CO6541628A2 (es) 2012-10-16
HK1174566A1 (en) 2013-06-14
ZA201204615B (en) 2013-09-25
EP2515855B3 (en) 2023-05-03
TN2012000269A1 (en) 2013-12-12
CY2017047I1 (el) 2018-04-04
CN104055765B (zh) 2016-11-23
UA113832C2 (xx) 2017-03-27
AU2018202998A1 (en) 2018-05-17
JP2013515696A (ja) 2013-05-09
TWI495468B (zh) 2015-08-11
MX2012006878A (es) 2012-07-04
HK1197036A1 (en) 2015-01-02
CA2785321C (en) 2018-08-21
EA201290375A1 (ru) 2013-01-30
KR101757951B1 (ko) 2017-07-13
LUC00060I2 (es) 2018-03-16
CL2012001705A1 (es) 2012-09-28
NO2018001I2 (no) 2018-01-10
JP2016145239A (ja) 2016-08-12
EP2515855B1 (en) 2014-04-02
NO2018001I1 (no) 2018-01-10
AU2016234895A1 (en) 2016-10-13
BR112012015337B8 (pt) 2021-05-25
NL300923I2 (en) 2019-07-22
HUS1800001I1 (hu) 2018-02-28
ES2468840T3 (es) 2014-06-17
ES2468840T7 (es) 2023-11-29
US20110150782A1 (en) 2011-06-23
EA201590179A1 (ru) 2015-09-30
PL2515855T3 (pl) 2014-08-29
LUC00060I1 (es) 2018-01-18
DK2515855T3 (da) 2014-06-30
NL300923I1 (en) 2018-01-17
PH12012501066A1 (en) 2016-03-02
CN102665679A (zh) 2012-09-12
US20190046433A1 (en) 2019-02-14
TW201129359A (en) 2011-09-01
BR112012015337B1 (pt) 2021-05-04
LTPA2018001I1 (lt) 2018-02-12
DK2515855T6 (da) 2023-06-06
MA33823B1 (fr) 2012-12-03
EA021917B1 (ru) 2015-09-30
HRP20140582T1 (hr) 2014-08-01
CY2017047I2 (el) 2018-04-04
CY1115116T1 (el) 2016-12-14
FI2515855T6 (fi) 2023-06-02
SG181868A1 (en) 2012-07-30
RS53391B (sr) 2014-10-31
HRP20140582T4 (hr) 2023-06-09
CN102665679B (zh) 2014-11-26

Similar Documents

Publication Publication Date Title
PE20160853A1 (es) Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
AR130239A2 (es) Método para reducir la cantidad del producto de degradación dp3 durante la vida de estante de una composición farmacéutica en solución para aerosol y uso de una lata de aerosol asociada
AR101593A2 (es) Formulación superfina de formoterol
ME02342B (me) Farmaceutske formulacije rastvora za izmjerene doze inhalatora pod pritiskom
AR038641A1 (es) Formulacion superfina de formoterol
AR067639A1 (es) Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente
ECSP088653A (es) Formulacion farmacéutica para aerosoles con dos o más principios activos y al menos una sustancia tensoactiva
NI201400139A (es) Nueva forma de dosificación y formulación de abediterol
PE20091672A1 (es) Nueva dosificacion y formulacion
WO2011076841A3 (en) Combination therapy for copd
UA106098C2 (uk) Аерозольна композиція для хозл
AR123674A2 (es) Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona
CL2023000998A1 (es) Formulación farmacéutica para inhalador presurizado de dosis medidas
BR0306663A (pt) Formulação de salmeterol superfino
JP2014520874A5 (es)
MX373699B (es) Composicion farmaceutica que contiene budesonida y formoterol.
AR094287A1 (es) Metodos y composiciones para administracion de oxibutinina
MX372705B (es) Composición farmacéutica que contiene budesonida y formoterol
AR085443A1 (es) Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero
TH127043A (th) ผลิตภัณฑ์รวมสำหรับบำบัด copd